Dynamic features of apo and bound HIV-Nef protein reveal the anti-HIV dimerization inhibition mechanism.
The first account on the dynamic features of Nef or negative factor, a small myristoylated protein located in the cytoplasm believes to increase HIV-1 viral titer level, is reported herein. Due to its major role in HIV-1 pathogenicity, Nef protein is considered an emerging target in anti-HIV drug design and discovery process. In this study, comparative long-range all-atom molecular dynamics simulations were employed for apo and bound protein to unveil molecular mechanism of HIV-Nef dimerization and inhibition. Results clearly revealed that B9, a newly discovered Nef inhibitor, binds at the dimeric interface of Nef protein and caused significant separation between orthogonally opposed residues, namely Asp108, Leu112 and Gln104. Large differences in magnitudes were observed in the radius of gyration (∼1.5 Å), per-residue fluctuation (∼2 Å), C-alpha deviations (∼2 Å) which confirm a comparatively more flexible nature of apo conformation due to rapid dimeric association. Compared to the bound conformer, a more globally correlated motion in case of apo structure of HIV-Nef confirms the process of dimeric association. This clearly highlights the process of inhibition as a result of ligand binding. The difference in principal component analysis (PCA) scatter plot and per-residue mobility plot across first two normal modes further justifies the same findings. The in-depth dynamic analyses of Nef protein presented in this report would serve crucial in understanding its function and inhibition mechanisms. Information on inhibitor binding mode would also assist in designing of potential inhibitors against this important HIV target.
a School of Health Sciences, University of KwaZulu-Natal , Durban , South Africa.
Suri
S
Moonsamy
a School of Health Sciences, University of KwaZulu-Natal , Durban , South Africa.
Soumendranath
S
Bhakat
a School of Health Sciences, University of KwaZulu-Natal , Durban , South Africa.
Mahmoud E S
ME
Soliman
D019380:Anti-HIV Agents / Q000737:chemistry / Q000494:pharmacology*; D001059:Apoproteins / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D001391:Azo Compounds / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites; D055808:Drug Discovery; D015497:HIV-1 / Q000737:chemistry / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D008958:Models, Molecular; D056004:Molecular Dynamics Simulation; D055503:Protein Multimerization / Q000187:drug effects; D017433:Protein Structure, Secondary; D011720:Pyrazoles / Q000737:chemistry / Q000494:pharmacology*; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000378:metabolism
D019380:Anti-HIV Agents; D001059:Apoproteins; D001391:Azo Compounds; C000609771:B9 Nef inhibitor; D011720:Pyrazoles; D054311:nef Gene Products, Human Immunodeficiency Virus; C514837:nef protein, Human immunodeficiency virus 1
B9; HIV-Nef; dimerization; molecular dynamics